Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa

Christen L Ebens*

Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited blistering skin disease, resulting from biallelic mutations in COL7A1, the gene encoding type VII collagen (C7). At mucocutaneous barriers, tissue integrity relies upon linked extracellular matrix (ECM) proteins forming a physiologic suture, connecting basal epidermal keratinocytes to the underlying dermis. C7 secreted from epidermal keratinocytes and dermal fibroblasts homotrimersizes in the upper dermis to form anchoring fibrils, a critical component of this suture. Clinical manifestations of RDEB are apparent at birth and include exquisite skin fragility, pain and itch, high metabolic demand, and complications downstream of systemic inflammation. Dermal fibrosis is a critical complication of RDEB. Repeated cycles of mechanical injury and healing trigger characteristic fibrotic changes. In addition to functional limitations from joint strictures and pseudosyndactyly formation, dermal fibrosis in RDEB is a nidus for and potential driver of aggressive squamous cell carcinoma (SCC), the leading cause of death in RDEB. A greater understanding of fibrosis in RDEB promises to inform impactful, lifelong clinical trials in this patient population with no proven systemic therapy or cure.

EMBO Mol Med (2021) 13: e14864
See also: R Bernasconi et al (October 2021)

Therapeutic developments in RDEB have largely centered on restoring C7 at the gene or protein level, either via local wound targeting treatments or via systemic therapies to address both external and internal disease manifestations. Local wound therapies under investigation include agents targeting specific COL7A1 mutations (premature termination codon readthrough agents), topical application of recombinant C7, use of gene-corrected autologous skin grafts, epidermal allografts following successful allogeneic hematopoietic cell transplantation, intradermal injection of mesenchymal stromal cells, and intradermal injection of gene-corrected autologous fibroblasts. However, impact of such interventions is limited to the skin, limited in body surface area covered, and limited in duration of benefit. Studies of systemic therapies to restore C7 are fewer in number to date. Until systemic sustained or lifelong therapeutic restoration of C7 is realized, patients with RDEB would benefit from alternative therapies to reduce disease burden and prolong life.

RDEB has been recognized as a disease of systemic inflammation, most apparent in persistently inflamed skin of affected patients, with marked erythema, acute, and chronic wounds at blister sites. Mucocutaneous wound repair is a complex process of cellular recognition of damage and response to restore tissue homeostasis. This process occurs by progression through phases of hemostasis, inflammation, proliferation, and remodeling. Impairment in any or multiple of these wound-healing phases may result in lack of healing (a chronic wound) or healing with fibrosis. Similar to the above experimental therapies, allogeneic hematopoietic cell transplantation (alloHCT) for RDEB began as a means to provide systemic C7 based on promising pre-clinical murine investigations. However, clinical response to alloHCT did not correlate with changes in cutaneous basement membrane C7. Interestingly, a population of donor-derived non-hematopoietic cells, presumed bone marrow-derived mesenchymal stromal cells (MSCs), were identified in the dermis (Tolar et al, 2011) raising question of an additional benefit of immunomodulation following alloHCT. MSCs are pluripotent cells with long-term self-renewal capacity allowing them to play important roles in tissue repair and homeostasis. They home to sites of injury/inflammation and modulate the microenvironment attracting reparative cells to wounded tissue and aiding in appropriate transition from the inflammatory phase of wound healing to proliferative and remodeling phases. MSCs have been shown to inhibit type I inflammatory responses by secretion of interleukin (IL)-1 receptor antagonist (Harrell et al, 2020) and to shift tissue macrophage differentiation toward anti-inflammatory M2 phenotype (Vander Beken et al, 2019). In the context of RDEB, MSC therapies have been investigated as standalone treatments as well as a supplement to alloHCT (Ebans et al, 2019).

The clinical benefit demonstrated by immunomodulatory MSCs in treatment of RDEB motivates further dissection of critical cell populations and pathways involved in acute and chronic cutaneous inflammation and ultimately fibrosis development. While circulating plasma levels of cytokines and immune cells is readily obtainable for assessment, tissue evaluations provide the most direct, valuable data. Transcriptomic analysis comparing RDEB to healthy skin has
demonstrated increased expression of genes involved in immune system activation (Breitenbach et al., 2015). Examinations of wound dressings (Fuentes et al., 2020) and blister fluid (Alexeev et al., 2017) highlight a plethora of neutrophils and lymphocytes recruited by chemokines and chemokine receptor ligands. While several proinflammatory cytokines, chemokines, and cell types have been associated with phenotypic severity in RDEB, few interventional pre-clinical studies describe successful interruption chronic inflammation with associated decrease in fibrosis.

In 2015, the Nystrom laboratory at the University of Freiburg in Germany elegantly demonstrated inhibition of TGF-β to reduce fibrosis of chronically injured forepaws in a murine model of RDEB (COL7A1-hypomorphic mice; Nystrom et al., 2015). Mass spectrometry-based tissue proteomics of less affected mouse back skin highlighted baseline elevation of inflammatory markers TNF-α and IL-6 in RDEB, reduced upon TGF-β inhibition. Alternative targeting of TGF-β with over-expression of decorin (an endogenous TGF-β inhibitor) demonstrated similar reduction in fibrosis of COL7A1-hypomorphic mice (Cianfarani et al., 2019). Expanding on these earlier findings, Nystrom’s group deployed multiple methods of analysis to unveil provocative age- and site-dependent differences in fibrosis in this same murine model of RDEB, association between inflammation and fibrosis progression, and promising reductions in fibrosis with the use of Ang-(1-7) (Bernasconi et al., 2021).

The COL7A1-hypomorphic mouse (Fritsch et al., 2008) demonstrates progressive fibrosis and early mortality paralleling the clinical course of severe, generalized RDEB in humans. Bernasconi et al. (2021) identified three time-points of fibrosis for comparative analysis of the RDEB mice, newborn (early injury), 4 weeks (mid-stage fibrosis), and 10 weeks (advanced fibrosis) of age. At each time-point, high-friction forepaws were compared with low-friction back skin, RDEB to wild-type (WT). Mass spectrometry tissue proteomics revealed RDEB forepaws to have increase over time in inflammatory pathway and fibroblast activation. Interestingly, this progressive fibrosis did not correlate with absolute increases in type I collagen but rather ECM remodeling (visually confirmed with picrosirius red staining). In addition to progressive fibrosis, flow cytometric analysis of immune cells in the RDEB skin revealed increase in neutrophils (over time) and CD38+ inflammatory macrophages (compared to WT), both cell populations phenotypically activated in forepaws, with high major histocompatibility complex (MHC) II expression. In RDEB mice, adaptive immune changes over time included increased CD4 T lymphocytes. Gene expression analysis of these T-cell populations shifted from a program of activation (increased Pdcd1 and CD27) at mid-fibrosis to that of exhaustion (increased Eomes and Pdcd1) at advanced fibrosis (Fig. 1A). These findings of early macrophage infiltrate and increase in T cells over time were replicated in human RDEB skin from different stages of fibrosis/ﬁbrosis.

Recognizing the stimulation of fibrosis by dysregulated inflammation, Bernasconi et al (2021) next devised an intervention to target both inflammatory cells and fibroblasts with a naturally occurring anti-inflammatory heptapeptide, Ang-(1-7). Ang-(1-7) is a member of the renin-angiotensin system (RAS), able to activate interconnected fibrosis-limiting axes of RAS and the kinin-kallikrein system (KKS). Following dose-finding studies, COL7A1-hypomorphic mice were treated systemically with one of 2 doses of Ang-(1-7) daily for 7 weeks, starting at the clinically relevant time-point of

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Analysis of time-dependent immune infiltrate and fibrosis in high-friction RDEB murine forepaws and impact of intervention with Ang-(1-7).

(A) Progressive fibrosis correlates with increase in innate immune infiltrate major histocompatibility complex (MHC) II expression and transition from an activated to exhausted phenotype of local adaptive immune cells. (B) Intervention with Ang-(1-7) upon onset of forepaw fibrosis engages fibrosis-limiting axes of the renin-angiotensin and kinin-kallikrein systems. In addition to forepaw and systemic decreases in RDEB target organ fibrosis, forepaw inflammatory processes are quelled.
visible paw deformities (5 weeks of age). Remarkably, Ang-(1-7) halted fibrosis progression and prolonged survival, with greatest benefit with Ang-(1-7) provided at low dose. While no reduction in inflammatory cells was achieved, MHC II expression was decreased on innate immune cells, consistent with a less activated state. Western blots of forepaw tissue lysates demonstrated low dose Ang-(1-7) to reduce TGF-β signaling, transitional ECM proteins and proteins associated with inflammatory potential. Visual assessment of treatment impact with picrosirius red staining found Ang-(1-7) associated with less remodeling of structural fibrils. Systemic effects were confirmed with decreases in fibrosis-associated proteins in major organs affected by fibrosis in RDEB, including the eye, tongue, and esophagus (Fig 1B). Parallel protein analyses of human RDEB fibroblasts and monocytic immune cells demonstrated consistent findings in vitro.

The Nyström group’s latest work in the pathophysiology of dermal fibrosis in RDEB provides a comprehensive longitudinal view of the interplay between type I immune activation, fibroblast activation, and ECM remodeling, including clinically relevant differences at sites of high vs. low friction. Murine findings were consistent in human samples, further supporting the validity of the COLA1-hypomorphic mouse as a model for human RDEB. Bernasconi et al (2021) provide additional robust pre-clinical data for the use of low dose Ang-(1-7) in halting progression of this inflammatory fibrosis. If successfully translated to human patients with RDEB, systemic reduction in progressive fibrosis may allow avoidance of esophageal failure, functional limitations in hand use and mobility, and ultimately may reduce or delay development of life-threatening SCC. Further, effective reductions in rates of dermal fibrosis may provide a more hospitable niche for future cellular therapies to restore C7 and permit positive clinical impact of the latter at advanced age. While this line of investigation supports strong pre-clinical data for trials of Ang-(1-7) in human RDEB, the potential disease-modifying benefit of immunomodulatory approaches is also supported.

References
Alexeev V, Salas-Alanis JC, Palisson F, Mukhtarzada L, Fortuna G, Litto J, South A, Igoucheva O (2017) Pro-inflammatory chemokines and cytokines dominate the blister fluid molecular signature in patients with epidermolysis bullosa and affect leukocyte and stem cell migration. J Invest Dermatol 137: 2298 – 2308
Bernasconi R, Thieme K, Romero-Fernández E, Gretzmeier C, Kühl T, Maler M, Nauroy P, Kleiser S, Rühl-Muth A-C, Stumpe M et al (2021) Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1–7). EMBO Mol Med 13: e14392
Breitenbach JS, Rinnerthaler M, Trost A, Weber M, Klaussegger A, Gruber C, Bruckner D, Reitsamer HA, Bauer JW, Breitenbach M (2015) Transcriptome and ultrastructural changes in dystrophic Epidermolysis bullosa resemble skin aging. Aging 7: 389 – 411
Cianfarani F, De Domenico E, Nyström A, Mastroeni S, Baldini E, Ulisse S, Uva P, Bruckner-Tuderman L, Zambroino C et al (2019) Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa. Matrix Biol 81: 3 – 16
Ebens CL, McGrath JA, Tamaki K, Hovnanian A, Wagner JF, Riddle MJ, Keene DR, DeFor TE, Tryon R, Chen M et al (2019) Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of non-hematopoietic cellular grafts. Br J Dermatol 181: 1238 – 1246
Fritsch A, Loeckermann S, Kern JS, Braun A, Bösl MR, Bley TA, Schumann H, von Elverfeldt D, Paul D, Erlacher M et al (2008) A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 118: 1669 – 1679
Fuentes I, Guttmann-Gruber C, Tockner B, Diem A, Klaussegger A, Cofré-Araneda G, Figuera O, Hidalgo Y, Morandé P, Palisson F et al (2020) Cells from discarded dressings differentiate chronic from acute wounds in patients with Epidermolysis Bullosa. Sci Rep 10: 15064
Harrell CR, Markovic BS, Fellabaum C, Arsenjevic N, Djonov V, Volarevic V (2020) The role of Interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration. BioFactors 46: 263 – 275
Nyström A, Thieme K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, Bruckner-Tuderman L (2015) Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. EMBO Mol Med 7: 1211 – 1228
Tolar J, Blazar BR, Wagner JE (2011) Concise review: Transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa. Stem Cells 29: 900 – 906
Vander Beken S, de Vries JC, Meier-Schiesser B, Meyer P, Jiang D, Sindirliarou A, Ferreira FF, Hainzl A, Schatz S, Muschhammer J et al (2019) Newly defined ATP-binding cassette subfamily B member 5 positive dermal mesenchymal stem cells promote healing of chronic iron-overload wounds via secretion of interleukin-1 receptor antagonist. Stem Cells 37: 1057 – 1074

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.